Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Norway Molecular Diagnostic Market: By Disease Type By Respiratory Infections By Virology and Country
Norway Molecular Diagnostic Market: By Disease Type By Respiratory Infections By Virology and Country
Norway Molecular Diagnostic Market size was valued at Euro 35.7 million in 2023 and is poised to grow at a significant CAGR of 7.2% from 2024-2030. The method of determining disease by examining molecules in a tissue or fluid, such as proteins, DNA, and RNA referred to as the molecular diagnosis. There are various types of kits available for different diseases which are based application on molecular biology techniques. CMV and EBV are the most commonly occurring infectious diseases in Norway. These tests are conducted for people with organ transplantation, bone marrow transplantation, immunocompromised patients, pregnant women, gastric cancer treatment cancer patients, and others.
Oslo University Hospital is one of the leading hospitals performing approximately 20,000 CMV tests annually. Oslo University Hospital has developed an in-house CMV test, CE marked. BKV, JCV, VZV, HSV, and Adenovirus in the blood and CSF are performed with PCR technique and Oslo University Hospital performs approximately 15 – 20 tests per day of each disease. Due to COVID-19, there has been reduced travel activity in large parts of Norway in 2020-2022, which also resulted in a marked decrease in screening tests for MRSA, VRE, and ESBL. Companies such as Amplex Diagnostics GmbH (Eazyplex VRE), Seegene, and BioMerieux offering commercial kits for VRE in Norway.
In Norway, high growth areas diseases in infectious and respiratory diseases are CMV, COVID-19, Influenza, RSV and in gastrointestinal bacterial, viral and parasitic diseases are more prominent. CMV infection is a common viral infection in humans, and approximately half of the population is unaware that they are infected with CMV. CMV infection is highly risky in pregnant women and people with weakened immune systems having HIV or who have had organ or stem cell transplants. The number of PCR tests for CMV diagnosis gradually increased over the historic years 2018 – 2022 across Norway.
In 2022, market volume accounted for 49,361 tests. The market volume is expected to grow at 2.5% CAGR over the forecast years to reach 57,296 tests by 2028. The new in vitro diagnostic regulation from the EU specifies, inter alia, rules for CE marking and approval of commercial and self-produced analyses for use in diagnostics. European Commission has just proposed new transitional rules. The rules for CE marking are very extensive, and the regulations are thus a threat to the laboratories' ability to set up self-produced tests in the years to come. In this sense, the regulation challenges the preparedness in the event of future pandemics. Internationally, it has also been pointed out how critically impaired SARS-CoV-2 diagnostics would have been if the regulation had been in force during this pandemic.
|
Report Benchmarks |
Details |
|
By Disease Type |
|
|
By Respiratory Infections |
|
|
By Virology |
|
Download Free Sample Report
Norway molecular diagnostic market size was valued at Euro 35.7 million in 2023 and is poised to grow at a significant CAGR of 7.2% from 2024–2030.
The major players in the market are QIAGEN, DiaSorin, Cepheid, Panther Fusion, Film Array, Seegene, Altona Diagnostics, Hologic, Siemens Healthineers, R-biopharma and BD Max
Increase in the incidence of infectious diseases such as CMV, EBV, gastrointestinal infections, and respiratory infections coupled with launched of advanced molecular diagnostic test kits and panels are surge the growth of market over the forecast years
| 1. Executive Summary |
| 2. Norway Molecular Diagnostic Market Introduction |
| 2.1. Norway Molecular Diagnostic Market - Taxonomy |
| 2.2. Norway Molecular Diagnostic Market - Definitions |
| 2.2.1.Disease Type |
| 2.2.2.Respiratory Infections |
| 2.2.3.Virology |
| 3. Norway Molecular Diagnostic Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Norway Molecular Diagnostic Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Norway Molecular Diagnostic Market By Disease Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Bacteria Panel |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Individual Panel |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Parasite Panel |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Viral Panel |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Gastrointestinal |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Norway Molecular Diagnostic Market By Respiratory Infections, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Bacteria Panel |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. COVID Panel |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Viral Panel |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Norway Molecular Diagnostic Market By Virology, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Individual Panel (Adenovirus, BKV, CMV, EBV, HSV, JCV, VZV |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 8. Competition Landscape |
| 8.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 8.2.1.QIAGEN |
| 8.2.2.DiaSorin |
| 8.2.3.BD Max |
| 8.2.4.Cepheid |
| 8.2.5.Panther Fusion |
| 8.2.6.Film Array |
| 8.2.7.Seegene |
| 8.2.8.Altona Diagnostics |
| 8.2.9.Hologic |
| 8.2.10.R-biopharma |
| 9. Research Methodology |
| 10. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.